Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06542965
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Characteristics Risk Factors and Resistance Mechanisms for Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to determine the clinical characteristics risk factors and resistance mechanisms of patients with carbapenem-resistant P mirabilis bacteremiaPatients with P mirabilis growth in blood culture samples sent to bacteriology laboratory between 2018 and 2021 were retrospectively analyzed Patients meeting the inclusion criteria were divided into carbapenem-resistant and carbapenem- susceptible groups The investigators recorded demographic data clinical features and laboratory findings Resistance genes were investigated in carbapenem-resistant isolates using PCR
Detailed Description:
Patients with P mirabilis growth in blood culture who met the study criteria were divided into two groups as carbapenem susceptible and resistant according to carbapenem antibiogram results Patients with carbapenem-resistant P mirabilis CRPM growth in blood culture were included in the case group and patients with carbapenem- susceptible P mirabilis CSPM growth in blood culture were included in the control group
Demographic characteristics of the patients concomitant chronic diseases Charlson comorbidity index CCI hospital and intensive care unit ICU hospitalization and number of days in the last year history and type of invasive intervention in the last three months surgical-invasive history of antibiotic use in the last three months and types of antibiotics used Penicillin cephalosporin quinolone carbapenem tigecycline colistin aminoglycoside hospitalization unit total length of hospitalization sample collection unit growth result and antibiogram clinical and laboratory data of the day of growth sepsis and septic shock evaluated according to systemic inflammatory response syndrome SIRS criteria 30-day mortality and patient outcome information were recorded
Carbapenemase-producing gene regions were investigated by Polymerase Chain Reaction PCR in accessible samples of patients with carbapenem-resistant P mirabilis growth in blood cultures
Demographic characteristics of the patients concomitant chronic diseases Charlson comorbidity index CCI hospital and intensive care unit ICU hospitalization and number of days in the last year history and type of invasive intervention in the last three months surgical-invasive history of antibiotic use in the last three months and types of antibiotics used Penicillin cephalosporin quinolone carbapenem tigecycline colistin aminoglycoside hospitalization unit total length of hospitalization sample collection unit growth result and antibiogram clinical and laboratory data of the day of growth sepsis and septic shock evaluated according to systemic inflammatory response syndrome SIRS criteria 30-day mortality and patient outcome information were recorded
Carbapenemase-producing gene regions were investigated by Polymerase Chain Reaction PCR in accessible samples of patients with carbapenem-resistant P mirabilis growth in blood cultures
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None